We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Novavax's pandemic influenza vaccine candidates triggered a protective immune response in several preclinical studies, according to data presented at the World Congress on Vaccines, Immunization and Immunotherapy.
Anadys Pharmaceuticals has initiated, in collaboration with Novartis, a 13-week preclinical toxicology study of ANA975 to assess safety and tolerability in animals.
Infinity Pharmaceuticals and MedImmune have announced preliminary results from an open-label Phase I clinical study of IPI-504 in patients with Gleevec-resistant metastatic gastrointestinal stromal tumors (GISTs).
Cytogen has announced results from a Phase I clinical trial of Quadramet (samarium Sm-153 lexidronam injection) in combination with hormonal therapy and external-beam radiation therapy in high-risk, clinically non-metastatic prostate cancer patients.
VIRxSYS has announced the publication of results from its Phase I, open-label, non-randomized clinical trial evaluating VRX496, a gene-based immunotherapy for the treatment of HIV.
Novartis announced that Prexige, a selective COX-2 inhibitor anti-inflammatory drug, has been cleared for approval in the European Union as a new treatment option for patients with osteoarthritis.
Omrix Biopharmaceuticals has submitted a biologics license application (BLA) to the FDA for approval to market thrombin as a standalone product with a general hemostasis indication in surgery.
Alnylam Pharmaceuticals has announced the publication of preclinical data demonstrating that an RNAi therapeutic can silence angiopoietin 2 (Ang2), a key mediator in acute lung injury.